Zura Bio’s (ZURA) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a report released on Monday morning,Benzinga reports. The firm currently has a $5.00 target price on the stock. HC Wainwright also issued estimates for Zura Bio’s Q3 2025 earnings at ($0.23) EPS.

Several other equities research analysts have also commented on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Chardan Capital lowered their target price on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Leerink Partners started coverage on Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. Finally, Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $15.80.

Zura Bio Stock Down 3.3 %

NASDAQ ZURA opened at $4.38 on Monday. Zura Bio has a 12-month low of $2.00 and a 12-month high of $6.35. The company has a fifty day simple moving average of $4.21 and a two-hundred day simple moving average of $4.13.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). On average, research analysts expect that Zura Bio will post -0.61 earnings per share for the current year.

Insider Activity

In other news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the sale, the director now directly owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC acquired a new stake in shares of Zura Bio during the 2nd quarter worth approximately $43,000. Renaissance Technologies LLC increased its stake in Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Zura Bio in the third quarter valued at $62,000. The Manufacturers Life Insurance Company acquired a new position in shares of Zura Bio in the 3rd quarter valued at $71,000. Finally, Valence8 US LP acquired a new position in shares of Zura Bio in the 3rd quarter valued at $71,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.